Background and Purpose-Both intracerebral hemorrhage (ICH) and brain edema have been attributed to reperfusion after intravenous thrombolysis. We explored the interaction of recanalization and core size for imaging outcomes (ICH and vasogenic brain edema). Methods-In patients with anterior circulation occlusion given intravenous thrombolysis <4.5 hours and imaged with computed tomographic (CT) perfusion and CT angiography, we defined volumes of core (relative delay time >2 s and relative cerebral blood flow <40%) and penumbra (relative delay time >2 s 
I ntravenous thrombolysis <4.5 hours after onset significantly improves outcome but carries increased risk of intracerebral hemorrhage (ICH). 1, 2 Reperfusion is proposed to be necessary both for ICH 3 and vasogenic brain edema, 4 the other major cause of early neurological deterioration after stroke.
Both the third International Stroke Trial (IST-3) 5 and pooled analysis of alteplase trials 6 indicated slight excess of fatal symptomatic ICH (SICH) within 7 days of treatment (2.7% in IST-3). IST-3 5 also reported a small excess risk of fatal brain swelling (1.5%) within 7 days, and the Alteplase Summary of Medicinal Product Characteristics (https://www. medicines.org.uk/emc/medicine/308section4.4) states that "reperfusion of the ischemic area may induce cerebral edema in the infarcted zone." Vasogenic edema was associated with increased blood-brain barrier permeability after reperfusion in a rodent model, 7, 8 but complex interactions of severity and duration of ischemia, and timing of reperfusion confound this possible relationship. 9 Space-occupying cerebral edema is clinically associated with large artery occlusions that recanalize rarely with intravenous recombinant tissue-type plasminogen activator (r-tPA), 10 and no excess risk of brain edema was reported in previous trials. 2, 11 Different types of hemorrhage may have different mechanisms and clinical implications: hemorrhagic infarction (HI1 or HI2 11 ) may be an epiphenomenon of reperfusion with no adverse clinical implications, whereas, in contrast, parenchymal hematomas with independent mass effect (PH1 or PH2 11 ) are linked with clinical worsening and may be related to blood-brain barrier breakdown after reperfusion.
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DEFUSE and the Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET) studies 14 found increased risk of PH1 or PH2 ICH when reperfusion occurred in patients with large core (large volumes of severely hypoperfused tissue on magnetic resonance imaging). Interaction of early reperfusion with other indices of severe ischemia (large diffusion weighted imaging volumes, 15 low cerebral blood volume on perfusion imaging, 16 or poor collaterals 17 ) has been reported for SICH after intravenous thrombolysis. The extent of vasogenic edema may also interact with ischemic core volume (>50% hypodensity on computed tomography (CT) was associated clinically with malignant brain edema 18 ) and in an animal model reperfusion of large volumes of severely ischemic tissue (cerebral blood flow [CBF] <40%) led to malignant edema. 19 Previous studies have not investigated the relationship of imaging characteristics (eg, ischemic core volume), reperfusion, and their interaction with brain edema and ICH after intravenous thrombolysis. We hypothesized that recanalization of large core (large ischemic area) would be associated with significant hemorrhage and persistent occlusion with significant brain edema (SBE).
Methods
We selected data from subjects treated with intravenous r-tPA of <4.5 hours after onset recruited at a single center to 1 of 3 multimodal imaging studies during 2008 to 2013. Two studies were observational (one investigating feasibility of complex imaging 20 and other investigating pathophysiology of acute hyperglycemia) and 1 was a trial comparing alteplase and tenecteplase (AlteplaseTenecteplase Trial Evaluation for Stroke Thrombolysis [ATTEST]: NCT01472926). 21 In the 2 observational studies, all patients with ischemic stroke aged >18 years and presenting <6 hours after onset were eligible. Exclusion criteria were contraindications to iodinated contrast (allergy or estimated glomerular filtration rate <30 mL/min). Patients underwent CT, CT angiography (CTA), and CT perfusion (CTP) at baseline with follow-up CT and CTA (if occlusion was present on baseline imaging) ≈24 hours later. Favorable outcome was defined as modified Rankin scale (mRS) score of 0 to 2 at a final review (30 or 90 days, depending on individual study). Endovascular treatment was not used.
Scans were acquired on a Philips Brilliance 64 multidetector scanner. Whole brain noncontrast computed tomography (NCCT) (5-mm slice thickness, field of view 218×218 mm, 120 kv, and 171 mA or 0.9-mm slice thickness, field of view 250×250 mm, 120 kV, and 404 mA) was followed by CTP with 40-mm slab coverage from the basal ganglia (8×5 mm slices, field of view 25 cm, 80 kVp, 476 mA, 2-s cycle time, and 30 cycles) using a 50-mL contrast bolus administered at 5 mL/s (350 Xenetix) via a large-gauge cannula. CTA covering aortic arch to the top of the lateral ventricles (0.67-mm slice thickness, 120 kV, and 475 mA) was acquired during the first arterial passage of contrast (Xenetix 350, 60 mL, followed by 30 mL of saline bolus, both given at 5 mL/s).
Anonymized imaging studies were analyzed independently by 2 researchers (B.K.C. and X.H.). CTP was processed offline using MiStar (Apollo Medical Imaging Technology, Melbourne, Australia). Deconvolution of tissue enhancement curves and arterial input function selected from the anterior cerebral artery was performed using modified singular value decomposition with compensation for the effects of arterial delay and dispersion. Delay time (DT) was determined by a delay-corrected singular value decomposition deconvolution by applying a series of DT values, with actual DT being minimum DT value, which produces T max =0. 22 DT and T max are related but are not identical, and because DT is derived from a vascular transport model correcting for arterial delay and dispersion, thresholds are smaller than T max . 23 DT has demonstrated superior correlation with tissue at risk in recent studies. 24 CBF and cerebral blood volume were calculated from the peak height and area under tissue enhancement curves, respectively, and mean transit time (MTT)=cerebral blood volume/CBF.
Ischemic core was defined as tissue with relative CBF of <40% of contralesional hemisphere and relative DT of >2 s; penumbra was defined as tissue with relative DT of >2 s but relative CBF of ≥40% of contralateral. 23 To account for limited z-axis coverage of CTP, we reduced the 70-mL threshold used by Extending the time for Thrombolysis in Emergency Neurological Deficits -Intra-Arterial (EXTEND-IA) 23 and DEFUSE-2 25 proportionately, by dividing the mean of (coregistered infarct volume >4 cm by Total Infarct volume from whole brain NCCT) in the nonrecanalized group: ≈70% of the total infarct was covered by the CTP slab; therefore, we considered large core to be of >50 mL. We evaluated baseline NCCT for ASPECT scores. 26 Collaterals on baseline CTA were graded if retrograde flow was seen on CTP source images, 27 and defined as good (vessels reconstitute distal to the occlusion), moderate (vessels seen partially in ischemic territory), or poor (contrast opacification seen only in distal superficial branches). We modified Miteff's classification to incorporate M2 occlusion (the original classification excluded M2 occlusion). 27 On 24-hour NCCT, we classified ICH as per European Cooperative Acute Stroke Study (ECASS)-2 criteria 11 and SICH as any ICH with increase in National Institutes of Health Stroke Scale (NIHSS) ≥4 points.
11 Any PH1 or PH2 were considered significant hemorrhage. Early vasogenic brain edema was classified as per IST-3 28 as no swelling (0), effacement of lateral ventricle (1), effacement of lateral plus third ventricles (2), or midline shift (3): we defined grades 2 to 3 as SBE. Recanalization was defined as thrombolysis in myocardial infarction (TIMI) grading 2 to 3 at 24-hour CTA. 29, 30 As an exploratory analysis, early major neurological improvement (NIHSS of 0 or 1 or improvement by ≥8 points by 24 hours) was taken as a biomarker of early reperfusion, and outcomes were compared among 3 groups: (1) no recanalization, (2) recanalization but no early improvement (presumed late recanalization), and (3) recanalization and early improvement (presumed early recanalization).
We compared groups by recanalization and ischemic core volume using χ 2 tests or Fisher exact tests for categorical variables and MannWhitney U tests for continuous variables. We evaluated the independent effect sizes of recanalization, core volume, and their interaction on imaging and clinical outcomes using logistic regression. Analyses used IBM SPSS Statistics (version 22). 
Results
Of 263 subjects, 159 had anterior circulation stroke with vessel occlusion pre treatment; we excluded 24 subjects presenting >4.5 hours after onset, and 12 in whom 24-hour CTA was not evaluable, leaving 123 subjects. Collateral grading was available in a subset of 106 subjects. Median age was 74 years (interquartile range, 62-80), median NIHSS was 15 (interquartile range, 9-20), and median symptom onset to treatment time was 180 minutes (interquartile range, 151-210). Occlusion site was ICA or M1 in 84 (68%). Recanalization on 24-hour CTA was seen in 80 (66%; tandem or proximal ICA 30%, M1 74%, M2 87%, and M3 50%; Table I in the online-only Data Supplement). Mean time interval from treatment to follow-up imaging was 27.5 hours (SD ±7). Detailed baseline characteristics are presented in Tables 1 and 2 Figure 2 ). Neither significant edema (12/92 alteplase treated versus 6/31 tenecteplase treated; odds ratio, 0.6; 95% confidence interval, 0.2-1.8; P=0.4) nor significant hemorrhage (8/92 alteplase treated versus 0/31 tenecteplase treated, P=0.2; odds ratio not calculable) was associated with thrombolytic agent.
After adjusting for 24-hour recanalization, large core (>50 mL) was associated with both hemorrhage and edema, most notably with SBE, although no significant relationship with PH1/PH2 ICH or SICH was evident. Recanalization was also associated with a trend toward any ICH, particularly HI1/2 ICH, but not to edema (Table 3) . Regression analysis did not identify significant interaction of large core and 24-hour recanalization for any outcome (Table 3) . Recanalization was associated with significantly reduced odds of death or dependence (mRS, 3-6) at day 30 or 90, whereas large core volume was associated with increased odds of these outcomes.
Early major improvement occurred in 36 patients: 45 had recanalized by 24 hours but did not exhibit early major improvement, and 38 showed no recanalization and no early improvement. Edema and hemorrhagic outcomes were generally lower and better in day 90 outcomes, in the group with presumed early recanalization but did not differ significantly between the late recanalizers and those with no recanalization (Table 4; Table II in the online-only Data Supplement).
Discussion
Recent focus on potential hazards of intravenous r-tPA highlights limited data on the interaction of patient characteristics, especially ischemic tissue volumes, reperfusion, and the pathophysiology of hemorrhage and brain edema. Few patients have been studied with detailed brain imaging, 14 only a proportion of whom have received thrombolytic therapy; animal models 19, 31 may not recapitulate the human situation, and other data derive from series of late endovascular intervention. 32 Our cohort allowed the study of interactions between 24-hour recanalization, perfusion characteristics, and incidence of both ICH and early brain edema. We found ICH incidence comparable with previous literature; for example, ICH of all kinds in 34% (48% in ECASS- 2 11 ) and SICH in 5.7% (7.7% in a meta-analysis 33 ). Incidence of early vasogenic brain edema of any degree (45%) and SBE (6.8%) are comparable with reported figures for edema 7 and SBE (4% in IST-3) 5 that used similar definitions, although other definitions yield variations in incidence. 34 Our recanalization rate (66%) was identical to that reported in the Interventional Management of Stroke (IMS)-3 r-tPA-treated group, as were recanalization rates by occlusion site. 35 The major predictor of ICH and SBE in our study was the presence of a large core. This is consistent with a rodent study in which infarct volume, but not reperfusion, was associated with edema. 36 Literature on reperfusion and postischemic edema in nonhuman primates examined only early time points (<6 hours) of unclear clinical relevance. 19, 37, 38 Recanalization in our study, in contrast, was associated only with a trend toward HI1/2 ICH. Neither recanalization, large core nor their interaction was associated with clinically relevant PH1/2 ICH. DEFUSE 13 reported potential interaction of large core and early reperfusion in provoking SICH and defined the malignant profile based on magnetic resonance imaging features similar to the CTP features in our study. Of 6 DEFUSE subjects with the malignant profile, 3 experienced (uniformly fatal) SICH. The combined EPITHET and DEFUSE studies 14 included only 27 malignant profile patients, of whom 6 of 9 who reperfused developed PH1/2 ICH, compared with 2 of 18 without reperfusion. Despite similar patient numbers, we were unable to replicate this interaction. Because perfusion characteristics may better define ICH risk than diffusion-weighted magnetic resonance imaging, 39 it seems unlikely that this is because of a difference between magnetic resonance imaging and CT-based tissue viability assessment methods.
As an exploratory analysis, we assessed major early clinical improvement as a biomarker of early reperfusion. This group had significantly fewer ICH or edema events and greater probability of favorable day 90 outcome. The incidence of significant ICH or edema did not differ between those with presumed late recanalization and those without recanalization, but it is not possible to exclude a relationship between late recanalization and adverse imaging outcomes.
Good clinical outcome was strongly associated with 24-hour recanalization (odds ratio, 2.8 [1.2-6.8]; P=0.02) and was less likely with large core (odds ratio, 0.15 [0.04-0.5]; P=0.03), consistent with previous observations, 40 but there was no significant interaction between these variables in predicting good 90-day outcome. This is consistent with the known prognostic value of both variables, 40, 41 but also with the lack of interaction between endovascular treatment effect and CTP features. 42 Our study has limitations. As a single center, retrospective analysis, independent replication in other settings is desirable. The small number of clinically significant hemorrhagic and brain swelling outcomes inevitably lead to wide confidence intervals around the effect estimates, encompassing the possibility that recanalization may be related to either significant edema or ICH, and means that conclusions must be cautious: nonetheless, with a larger number of outcome events we were unable to replicate earlier reports of an association with ICH, as discussed above. No classification of brain edema has been reported consistently in clinical studies, and different classification methods may yield different incidence. The timing of brain imaging for outcome assessment in our data set (mean 27.5 hours after intravenous thrombolysis) is too early to detect maximal brain swelling, but although this might underestimate the severity of brain edema, it seems unlikely to underestimate the incidence of SBE based on data that indicate that 95% of cases progressing to malignant middle cerebral artery infarction were identifiable on 24-hour CT. 34 CTP analysis was based on validated thresholds, but standardization is not yet agreed. 43 Because we had access to angiographic outcome data only at ≈24 hours, we could not discriminate early from although we undertook exploratory analyses using early clinical improvement as a biomarker for this. We used TIMI 2 to 3 (partial or complete recanalization) because even partial restoration of flow might be expected to affect on adverse complications, whereas TIMI 3 would be more strongly related to favorable clinical outcomes, which was an end point of secondary interest in this study. The overall recanalization rate at 24 hours in our study (66%) matches that reported by the IMS-3 (65%) based on a 24-h CTA end point, with comparable individual occlusion site recanalization rates, 35 offering further reassurance about external validity.
Our findings indicate that 24-hour recanalization itself is not significantly associated with early vasogenic edema, or significant hemorrhage, questioning the widespread attribution of these outcomes to reperfusion injury. The association of large core with both significant edema, and also poor outcome in spite of recanalization, is consistent with the recent clinical trial strategies that have sought to exclude such patients from reperfusion therapies. Observational data cannot define risk: benefit ratio, however, and it is important to bear in mind that excluding large core patients might represent an efficient clinical trial strategy, but that risk: benefit balance in this group remains to be determined: treatment in this group may still be associated with net benefit.
Conclusions
Among patients treated with intravenous r-tPA, 24-hour recanalization was not independently associated with significantly early (24 hours) vasogenic edema or significant hemorrhage, although incidence of HI/HI2 ICH was higher. Large ischemic core was associated with both SBE and poor outcome. There was no interaction of recanalization and large core lesions for any imaging outcomes. Early major clinical improvement as a marker of probable early reperfusion was associated with lower incidence of both significant hemorrhage and edema.
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